Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19042264 | PHOSPHATE SENSING MICROBIAL GENE SWITCH | January 2025 | February 2026 | Allow | 12 | 2 | 1 | Yes | No |
| 18646267 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | April 2024 | November 2025 | Allow | 19 | 1 | 0 | No | No |
| 18617782 | PHAGE-DERIVED PARTICLES FOR IN SITU DELIVERY OF DNA PAYLOAD INTO C. ACNES POPULATION | March 2024 | July 2025 | Allow | 15 | 1 | 0 | No | No |
| 18491484 | ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN BETA-2 MICROGLOBULIN GENE | October 2023 | September 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18490484 | DYSTROPHIN GENE EXON DELETION USING ENGINEERED NUCLEASES | October 2023 | September 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18487610 | SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE) | October 2023 | August 2024 | Allow | 10 | 1 | 0 | No | No |
| 18471187 | METHODS OF TREATING EYE DISEASES | September 2023 | January 2026 | Allow | 28 | 3 | 0 | Yes | No |
| 18461798 | CHO INTEGRATION SITES AND USES THEREOF | September 2023 | October 2025 | Allow | 26 | 1 | 0 | No | No |
| 18326689 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | May 2023 | December 2025 | Allow | 31 | 2 | 0 | No | No |
| 18326708 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | May 2023 | July 2025 | Allow | 26 | 1 | 0 | No | No |
| 18326634 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | May 2023 | July 2025 | Allow | 26 | 2 | 0 | Yes | No |
| 18326588 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | May 2023 | November 2024 | Allow | 17 | 2 | 0 | Yes | No |
| 18324926 | RNA TARGETING METHODS AND COMPOSITIONS | May 2023 | September 2025 | Abandon | 28 | 1 | 1 | No | No |
| 18314411 | HUMAN INNATE LYMPHOID CELL PRECURSORS: IDENTIFICATION, CHARACTERIZATION, APPLICATIONS | May 2023 | May 2025 | Abandon | 25 | 2 | 0 | No | No |
| 18152367 | NOVEL ENZYMATIC METHODS TO GENERATE HIGH YIELDS OF SEQUENCE SPECIFIC RNA OLIGONUCLEOTIDES WITH EXTREME PRECISION | January 2023 | February 2025 | Allow | 25 | 1 | 0 | No | No |
| 18088683 | Adult stem cell compositions and methods of identification and isolation | December 2022 | August 2025 | Allow | 32 | 3 | 1 | No | No |
| 18007667 | QUANTIFICATION OF CORONAVIRUS RNAAEMIA | December 2022 | January 2026 | Abandon | 38 | 0 | 1 | No | No |
| 17992039 | Method for increasing the specific production rate of eukaryotic cells | November 2022 | February 2025 | Allow | 27 | 1 | 0 | No | No |
| 17913638 | INACTIVATED SARS-COV-2 VIRUS VACCINE | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17906784 | HAPTENIZED CORONAVIRUS SPIKE PROTEINS | September 2022 | December 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17798051 | COMPOSITION AND METHOD OF mRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION | August 2022 | December 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17861207 | NUCLEASE CASCADE ASSAY | July 2022 | November 2024 | Abandon | 28 | 2 | 2 | No | No |
| 17811138 | TARGETING PD-L1 ON TUMOR CELLS | July 2022 | April 2025 | Allow | 33 | 3 | 0 | No | No |
| 17810373 | PLASMID ADDICTION SYSTEM TO DRIVE DESIRED GENE EXPRESSION | July 2022 | January 2026 | Allow | 42 | 3 | 1 | No | No |
| 17854371 | MEANS AND METHODS FOR AAV GENE THERAPY IN HUMANS | June 2022 | October 2024 | Allow | 28 | 2 | 0 | No | No |
| 17854870 | RECOMBINANT PROTEIN COMPRISING MULTIPLE MULTI-PEPTIDE SETS, PHARMACEUTICAL COMPOSITION COMPRISING THE RECOMBINANT PROTEIN, AND METHOD FOR PREPARING THE RECOMBINANT PROTEIN | June 2022 | July 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17846620 | Compositions and Methods Relating to Synthetic RNA Polynucleotides Created From Synthetic DNA Oligonucleotides | June 2022 | October 2025 | Allow | 39 | 4 | 0 | No | No |
| 17757201 | MATERIALS AND METHODS FOR INFLAMMATORY MOLECULAR MARKERS | June 2022 | November 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17664006 | CANCER BIOMARKERS AND METHODS OF USE THEREOF | May 2022 | September 2023 | Allow | 16 | 3 | 0 | No | No |
| 17746008 | METHODS FOR HARVESTING MAMMALIAN CELL CULTURES | May 2022 | September 2024 | Allow | 28 | 2 | 1 | No | No |
| 17662422 | ANTIGEN AND ANTIBODIES PREPARED BASED ON PADI4 SERVING AS TUMOR MARKER, AND APPLICATION THEREOF | May 2022 | January 2026 | Allow | 44 | 1 | 1 | No | No |
| 17713025 | OLIGONUCLEOTIDES WITH NUCLEOSIDE ANALOGS | April 2022 | March 2026 | Allow | 47 | 1 | 1 | No | No |
| 17765170 | Oligonucleotide based ex vivo cell therapy | March 2022 | October 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17703782 | NUTRIENT COMPOSITIONS AND METHODS, KITS, AND CELL COMPOSITIONS FOR PRODUCING THE SAME | March 2022 | February 2025 | Abandon | 35 | 5 | 1 | Yes | No |
| 17688190 | METHODS FOR THE DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS | March 2022 | April 2025 | Allow | 38 | 4 | 1 | No | No |
| 17565796 | ADENOVIRUS POLYNUCLEOTIDES AND POLYPEPTIDES | December 2021 | September 2025 | Abandon | 45 | 3 | 1 | No | No |
| 17558406 | ENHANCED PROTEIN PURIFICATION THROUGH A MODIFIED PROTEIN A ELUTION | December 2021 | November 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17616061 | COMPOUNDS AND METHODS FOR INHIBITING CANCERS VIA REST INHIBITION | December 2021 | September 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17493469 | COMPOSITIONS AND METHODS FOR T-CELL RECEPTOR GENE ASSEMBLY | October 2021 | March 2025 | Allow | 41 | 2 | 0 | No | No |
| 17412664 | ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES | August 2021 | November 2025 | Allow | 51 | 2 | 1 | No | No |
| 17395552 | PRODUCTION METHODS FOR MEGAKARYOCYTES AND PLATELETS | August 2021 | February 2026 | Abandon | 55 | 4 | 0 | No | No |
| 17310107 | CELL SPECIFIC TRANSCRIPTIONAL REGULATORY SEQUENCES AND USES THEREOF | July 2021 | February 2025 | Allow | 43 | 1 | 1 | No | No |
| 17418465 | ENCAPSULATED RNA POLYNUCLEOTIDES AND METHODS OF USE | June 2021 | October 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17309808 | APP MODIFICATION VIA BASE EDITING USING THE CRISPR/CAS9 SYSTEM | June 2021 | March 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17415626 | GENETIC MODIFICATION OF THE HYDROXYACID OXIDASE 1 GENE FOR TREATMENT OF PRIMARY HYPEROXALURIA | June 2021 | September 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17312174 | CRISPR-CAS-BASED COMPOSITION FOR GENE CORRECTION | June 2021 | August 2025 | Allow | 50 | 2 | 1 | No | No |
| 17312324 | ANTI-CRISPR-MEDIATED CONTROL OF GENOME EDITING AND SYNTHETIC CIRCUITS IN EUKARYOTIC CELLS | June 2021 | February 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17299034 | CELL-BASED BIOIDENTITY TEST FOR INSULIN | June 2021 | December 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17334862 | METHODS OF ACTIVATING DYSFUNCTIONAL IMMUNE CELLS AND TREATMENT OF CANCER | May 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17216303 | MATERIALS AND METHODS FOR TREATMENT OF AUTOSOMAL DOMINANT CONE-ROD DYSTROPHY | March 2021 | July 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17182142 | METHODS AND COMPOSITIONS FOR AIDING IN THE DETECTION OF LUNG CANCER | February 2021 | May 2025 | Abandon | 51 | 2 | 1 | No | Yes |
| 17270170 | METHODS OF TREATING CANCER | February 2021 | April 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17269741 | RECOMBINANT VIRUS PRODUCTS AND METHODS FOR INHIBITING EXPRESSION OF DYSTROPHIA MYOTONICA PROTEIN KINASE AND/OR INTERFERING WITH A TRINUCLEOTIDE REPEAT EXPANSION IN THE 3' UNTRANSLATED REGION OF THE DMPK GENE | February 2021 | August 2025 | Allow | 53 | 2 | 1 | No | No |
| 17269490 | AGENT USING HSP47 INHIBITOR TO SUPPRESS METASTASIS | February 2021 | July 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17175324 | METHOD FOR SCALABLE SKELETAL MUSCLE LINEAGE SPECIFICATION AND CULTIVATION | February 2021 | June 2025 | Abandon | 52 | 1 | 0 | No | No |
| 17166004 | Delta133P53Beta and Delta133P53Gamma Isoforms Are Biomarkers of Cancer Stem Cells | February 2021 | August 2024 | Allow | 42 | 3 | 0 | No | No |
| 17152025 | TREATMENT OF RETINAL DEGENERATION USING GENE THERAPY | January 2021 | December 2025 | Abandon | 59 | 4 | 0 | No | No |
| 17260804 | METHODS FOR SAFELY REDUCING THROMBOPOIETIN | January 2021 | August 2025 | Allow | 55 | 3 | 0 | Yes | No |
| 17260071 | METHOD FOR EDITING DNA IN CELL-FREE SYSTEM | January 2021 | November 2025 | Abandon | 58 | 3 | 0 | Yes | No |
| 17254191 | METHODS OF AAV THERAPY | December 2020 | January 2025 | Allow | 49 | 1 | 1 | No | No |
| 17251104 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES | December 2020 | September 2025 | Abandon | 58 | 3 | 1 | Yes | No |
| 17057628 | BIOMARKERS FOR DIAGNOSING TUBERCULOUS MENINGITIS | November 2020 | August 2024 | Allow | 45 | 1 | 1 | No | No |
| 17053148 | COMPOSITIONS AND METHODS FOR CULTURING AND EXPANDING CELLS | November 2020 | April 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17090807 | FURTHER IMPROVED AAV VECTORS PRODUCED IN INSECT CELLS | November 2020 | June 2025 | Allow | 56 | 5 | 1 | No | No |
| 17051578 | IMPROVED BCL11A MICRORNAS FOR TREATING HEMOGLOBINOPATHIES | October 2020 | March 2025 | Allow | 52 | 2 | 1 | No | No |
| 17050686 | HIGHLY ACCURATE SEQUENCING METHOD | October 2020 | February 2026 | Allow | 60 | 2 | 0 | Yes | No |
| 16934573 | MYELIN OLIGODENDROCYTE GLYCOPROTEIN, MYELIN BASIC PROTEIN, AND PROTEOLIPID PROTEIN COMPOSITIONS AND METHODS OF USE | July 2020 | June 2025 | Allow | 59 | 3 | 1 | No | No |
| 16885162 | SYSTEMS AND METHODS TO DETECT STEM CELL STRESS AND USES THEREOF | May 2020 | September 2025 | Abandon | 60 | 4 | 1 | Yes | No |
| 16759251 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | April 2020 | September 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16480273 | SYSTEMS AND METHODS FOR IMMUNOMODULATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS | July 2019 | July 2024 | Allow | 60 | 3 | 1 | Yes | No |
| 16435710 | METHOD OF EVALUATING NEUTROPHIL ACTIVITY | June 2019 | June 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16432107 | POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC PROTEINS AND THEIR USE IN GENE THERAPY | June 2019 | April 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16463886 | AGENTS FOR THE TREATMENT OF PATIENTS WITH NSCLC AND METHODS TO PREDICT RESPONSE | May 2019 | December 2024 | Abandon | 60 | 1 | 1 | No | No |
| 16415187 | PROTEIN EXPRESSION STRAINS | May 2019 | March 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16355932 | ENGINEERING OF BACTERIOPHAGES BY GENOME EDITING USING THE CRISPR-CAS9 SYSTEM | March 2019 | March 2026 | Abandon | 60 | 6 | 1 | Yes | Yes |
| 16334269 | METHOD FOR EVALUATING THE EYE IRRITATION POTENTIAL OF CHEMICALS | March 2019 | July 2025 | Allow | 60 | 5 | 1 | Yes | No |
| 16307708 | Herpesvirus with Modified Glycoprotein H for Propagation in a Cell | December 2018 | December 2025 | Allow | 60 | 6 | 1 | No | No |
| 16305003 | PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR DELIVERY OF GENOME-EDITING MOLECULES | November 2018 | January 2025 | Abandon | 60 | 3 | 2 | No | No |
| 16092761 | MASSIVELY MULTIPLEXED HOMOLOGOUS TEMPLATE REPAIR FOR WHOLE-GENOME REPLACEMENT | October 2018 | April 2024 | Abandon | 60 | 5 | 0 | No | No |
| 16144822 | METHODS FOR PROMOTING OLIGODENDROCYTE REGENERATION AND REMYELINATION | September 2018 | December 2024 | Abandon | 60 | 5 | 0 | No | No |
| 16011263 | PLASMA CELL CYTOKINE VEHICLE CONTAINING FUSION PROTEINS FOR TARGETED INTRODUCTION OF SIRNA INTO CELLS AND TISSUES | June 2018 | July 2019 | Allow | 13 | 1 | 1 | No | No |
| 15909666 | METHOD FOR SCREENING INDUCED PLURIPOTENT STEM CELLS | March 2018 | May 2019 | Allow | 14 | 1 | 0 | No | No |
| 15575325 | SCREENING METHODS FOR TARGETS FOR CANCER THERAPY | November 2017 | July 2020 | Abandon | 32 | 8 | 1 | Yes | Yes |
| 15709144 | HOMOLOGOUS RECOMBINATION IN MULTIPOTENT ADULT PROGENITOR CELLS | September 2017 | October 2019 | Allow | 25 | 2 | 0 | No | No |
| 14909713 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | February 2016 | April 2019 | Allow | 39 | 2 | 1 | No | No |
| 14960136 | DNA MOLECULES AND METHODS | December 2015 | September 2019 | Allow | 46 | 4 | 1 | No | No |
| 14655744 | PGC-1beta-Protein-Function Regulator, Mitochondria-Function Regulator, Anti-Obesity Agent, And Screening Method Therefor | August 2015 | May 2017 | Allow | 23 | 1 | 1 | No | No |
| 14414253 | METHOD FOR IDENTIFYING MOLECULAR MARKERS OF CHILDREN'S SKIN | June 2015 | January 2026 | Allow | 60 | 11 | 1 | Yes | No |
| 14669957 | MIXER FOR REMOVING IMPURITIES FROM GASES AND LIQUIDS | March 2015 | June 2015 | Allow | 3 | 0 | 0 | No | No |
| 14415064 | Hypoxia Inducible Factor (HIF) Activity Reporter Cell Line | January 2015 | March 2018 | Allow | 38 | 4 | 1 | No | No |
| 14345745 | miRNA Biomarkers For Ulcerative Colitis | September 2014 | March 2017 | Allow | 36 | 2 | 1 | No | No |
| 14084030 | Gene Cluster for Biosynthesis of Cornexistin and Hydroxycornexistin | November 2013 | June 2017 | Allow | 43 | 3 | 1 | No | No |
| 13944979 | Enrichment of Stem Cells from Adult Tissues | July 2013 | November 2015 | Allow | 27 | 1 | 0 | No | No |
| 13864778 | METHOD FOR DETERMINING THE NEURODEVELOPMENTAL TOXICITY OF A COMPOUND IN VITRO | April 2013 | June 2017 | Allow | 50 | 3 | 0 | No | No |
| 13800478 | Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same | March 2013 | June 2014 | Allow | 15 | 1 | 1 | No | No |
| 13572067 | BIOMARKERS OF CANCER METASTASIS | August 2012 | January 2014 | Allow | 17 | 2 | 0 | Yes | No |
| 13476305 | ANF-RGC IN-GENE KNOCK-OUT ANIMAL | May 2012 | June 2014 | Allow | 25 | 4 | 1 | No | No |
| 13454171 | PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME | April 2012 | April 2014 | Allow | 24 | 3 | 0 | Yes | No |
| 13361628 | CELL CULTURE SYSTEM FOR DETERMINING THE SENSITIZING, ALLERGENIC AND/OR IRRITATING EFFECT OF A SUBSTANCE | January 2012 | July 2015 | Allow | 41 | 4 | 0 | No | No |
| 13328785 | BIOMARKER DACT1 FOR GASTRIC CANCER | December 2011 | June 2015 | Allow | 42 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner QIAN, CELINE X.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 30.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner QIAN, CELINE X works in Art Unit 1637 and has examined 179 patent applications in our dataset. With an allowance rate of 82.1%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 44 months.
Examiner QIAN, CELINE X's allowance rate of 82.1% places them in the 54% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by QIAN, CELINE X receive 2.67 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by QIAN, CELINE X is 44 months. This places the examiner in the 14% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a -0.4% benefit to allowance rate for applications examined by QIAN, CELINE X. This interview benefit is in the 12% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 23.6% of applications are subsequently allowed. This success rate is in the 33% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 48.0% of cases where such amendments are filed. This entry rate is in the 72% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 86.7% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 92.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 76.9% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 14.0% of allowed cases (in the 96% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.7% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.